March 21, 2018Open Access
View Full PaperVenetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Key Points
Key points are not available for this paper at this time.
Abstract
Among patients with relapsed or refractory chronic lymphocytic leukemia, venetoclax plus rituximab resulted in significantly higher rates of progression-free survival than bendamustine plus rituximab. (Funded by Genentech and AbbVie; ClinicalTrials.gov number, NCT02005471 .).